Revance CEO Mark Foley joins Yahoo Finance Live to discuss the therapeutic company's anti-wrinkle Daxxify treatment, its multi-use purposes, and its competition with traditional Botox injections.
Revance Shares Jump 18% After FDA Approves Botox Rival Daxxify
The FDA approved Daxxify for temporary improvement of moderate to severe frown lines, Revance said in a Thursday morning statement. Shares of Revance climbed gradually Thursday afternoon, trading at ...
Does Botox for Sweating Actually Work? We Asked a Dermatologist
If you’re a particularly sweaty person, you know how inconvenient, uncomfortable and sometimes downright embarrassing it can be. (You know, like when you spend the year before your sister’s wedding ...
What to Know About Botox Injections for Migraine Treatment
It’s a great era in headache medicine because we have many different medications, including Botox for migraines, to help people to have as little restriction from their activities as possible.” Many ...
This ‘No Botox Serum’ Makes Shoppers’ Skin Look ‘Firmer & Younger’ After a Few Uses
The brand has so many amazing formulas, like the CELLRENEW Collagen Stem Cell Serum and CLEARITY Mandelic Acid Serum, but today, I’m shining the spotlight on the BOUNCEBACK Serum—also referred to as ...
Botox rival from Revance gets U.S. approval
The U.S. Food and Drug Administrationon Thursday approved Revance Therapeutics' anti-wrinkle injection, setting up a challenger for market leader AbbVie's Botox that has long dominated the aesthetic ...
Revance Shares Jump 17% After FDA Approves Botox Rival
Shares of Revance Therapeutics surged 18% Thursday after the company announced the Food and Drug Administration had approved Daxxify, a facial injection drug that Revance hopes will challenge Botox’s ...
Botox rival’s longer-lasting wrinkle eraser approved by FDA: ‘It’s a big deal’
The Food and Drug Administration has approved a new wrinkle-erasing treatment that could be a serious competitor to Botox, the Wall Street Journal reported Inc’s Daxxify — known also as ...
F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor
The treatment lasts for six months in half of its users, company studies showed, representing the first major advance in facial injections in decades.